DF-003 is the first ALPK1 inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (NCT06395285), where it is ...
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...
Raises 2026 Financial Guidance Ranges: – Increases Total Revenue to $1,710 – $1,810 million, YoY Growth of 23% to 30%2 – ...
It's unlikely Starmer will land a deal on heavy energy infrastructure, including wind turbine technology, that could leave ...
FOX News on MSN
Iranian regime has wasted their wealth on 'maligned activities,' State Department official says
tate Department principal deputy spokesman Tommy Pigott unpacks Secretary of State Marco Rubio’s Senate hearing testimony on ...
Explore groundbreaking research on ALS and how a specific mouse strain could change its study and treatment forever.
Federal cannabis policy is entering 2026 in a “split-screen” posture: marijuana appears to be moving toward a less restrictive federal status, ...
Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.
Learn how dedicated developers turned initial failures into some of today's most beloved multiplayer games that only became ...
In 2010, third-party sellers (independent merchants selling products on Amazon) were responsible for roughly one-third of all units sold on the platform, according to Marketplace Pulse data. Today, 62 ...
The integrated solution delivers a shift-left approach to cybersecurity, enabling executive teams to proactively embed security, quality, and compliance from early development to post-market. When ...
Roche remains a Buy, driven by strong pipeline progress and conservative valuation, with shares up 36% since my last recommendation. Learn more about RHHBY stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results